TORONTO, May 27, 2025 /CNW/ - Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada. Otulfi ™ is indicated for the ...

With this launch, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Tyenne ® is Fresenius ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce that the UK Medicines and Healthcare products Regulatory ...

With this approval, Fresenius Kabi Canada's immunology biosimilar portfolio is further expanding, offering more treatment options for patients with chronic autoimmune conditions Otulfi TM is ...

LAKE ZURICH, Ill., November 14, 2024--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, announced today it received a Novaplus Program Excellence Award from Vizient, Inc., the ...

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announces they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs).

Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies ...

Injectable medicine and biosimilar maker Fresenius Kabi said today Arunesh Verma is the new president of Lake Zurich-based Fresenius Kabi USA. He succeeds John Ducker, who is retiring after 35 ...

Fresenius Kabi Philippines, Inc.—a global healthcare company that focuses on lifesaving medicines for infusion, transfusion, and clinical nutrition welcomed the first quarter of the year with ...

Fresenius Kabi began the recall at the end of November. It covers only LVP-0004 models of the large-volume pump that were distributed between October 2021 and July of last year—938 of which were ...